{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-045865","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.192494+00:00","generated_at":"2026-05-22T05:32:37.101356+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"confidence":"high","headline":"Zura Bio Q1 net loss $17.4M; cash $170.6M; trial on track","bullets":["Net loss $17.4M ($0.19/sh) vs $7.7M ($0.02/sh) in Q1 2024; R&D spend $10.5M (+192% YoY).","Cash and equivalents $170.6M; runway expected to fund operations through 2027.","Phase 2 TibuSURE trial for systemic sclerosis continues; HS Phase 2 expected Q2 2025.","Appointed Kate Dingwall as SVP of Development Operations to support clinical execution.","G&A expenses $8.8M, increased $4.0M YoY due to compensation and professional fees."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-045865","json":"https://secwatch.observer/filing/0001104659-25-045865.json","markdown":"https://secwatch.observer/filing/0001104659-25-045865.md","text":"https://secwatch.observer/filing/0001104659-25-045865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465925045865/0001104659-25-045865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465925045865/tm2514121d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:32:37.101356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}